Identification of the breakpoints at 1p36.2 and 3p21.3 in an AML(M3) patient who had t(1;3)(p36.2;p21.3) at the third relapse

Nguyen Khanh Tri, Phan Thi Xinh, Hiromasa Nagao, Tohru Izumi, Keiya Ozawa, Atsushi Toyoda, Masahira Hattori, Yoshiyuki Sakaki, Katsushi Tokunaga, Yuko Sato

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Recently, we reported that a recurrent translocation, t(1;3)(p36;p21) is closely associated with prior chemotherapy including alkylating agents, assessing eight patients with various hematologic malignancies (Genes, Chromosomes and Cancer 34:186- 192), 2002). Furthermore, we delineated the 1p36 breakpoint in two patients lying between RP11-BAC47P3 and RP5-PAC963K15 at 1p36.3 with a small deletion near the breakpoint. In one of them, we also found deletion at 3p21.3 with cosNRL9 probe, which is included in a 370-kb lung cancer homologous deletion region. However, due to scantiness of the patient materials at that time, we could not determine the precise breakpoint at 1p36 or 3p21 in any of the patients. In this report, we identified the 1p36 and 3p21 breakpoints of an AML (M3) patient who is included in the previous patient series. The patient showed t(1;3)(p36;p21) together with t(15;17) at the third relapse. With FISH using BAC/PAC probes, we determined the 1p36 breakpoint within RP11-295B1 at 1p36.2 and the 3p21 breakpoint between RP11-3B7 and RP11-901L6 at 3p21.3. There was no deletion around the two breakpoints in this patient. To the best of our knowledge, this is the first report that has identified the precise breakpoint of t(1;3)(p36;p21) transiocation. It is obvious that the 1p36.2 and 3p21.3 breakpoints of this patient are different from those of the previous patients, suggesting that the genes and the molecular event is different from those of the previous patients. The patients with t(1;3)(p36;p21) should be subclassified according to the precise breakpoints or the genes involved.

Original languageEnglish
Pages (from-to)365-367
Number of pages3
JournalGenes Chromosomes and Cancer
Volume35
Issue number4
DOIs
Publication statusPublished - 2002 Dec 1
Externally publishedYes

Fingerprint

Acute Promyelocytic Leukemia
Recurrence
Neoplasm Genes
Alkylating Agents
Hematologic Neoplasms
Genes
Lung Neoplasms
Chromosomes

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Identification of the breakpoints at 1p36.2 and 3p21.3 in an AML(M3) patient who had t(1;3)(p36.2;p21.3) at the third relapse. / Tri, Nguyen Khanh; Xinh, Phan Thi; Nagao, Hiromasa; Izumi, Tohru; Ozawa, Keiya; Toyoda, Atsushi; Hattori, Masahira; Sakaki, Yoshiyuki; Tokunaga, Katsushi; Sato, Yuko.

In: Genes Chromosomes and Cancer, Vol. 35, No. 4, 01.12.2002, p. 365-367.

Research output: Contribution to journalArticle

Tri, NK, Xinh, PT, Nagao, H, Izumi, T, Ozawa, K, Toyoda, A, Hattori, M, Sakaki, Y, Tokunaga, K & Sato, Y 2002, 'Identification of the breakpoints at 1p36.2 and 3p21.3 in an AML(M3) patient who had t(1;3)(p36.2;p21.3) at the third relapse', Genes Chromosomes and Cancer, vol. 35, no. 4, pp. 365-367. https://doi.org/10.1002/gcc.10130
Tri, Nguyen Khanh ; Xinh, Phan Thi ; Nagao, Hiromasa ; Izumi, Tohru ; Ozawa, Keiya ; Toyoda, Atsushi ; Hattori, Masahira ; Sakaki, Yoshiyuki ; Tokunaga, Katsushi ; Sato, Yuko. / Identification of the breakpoints at 1p36.2 and 3p21.3 in an AML(M3) patient who had t(1;3)(p36.2;p21.3) at the third relapse. In: Genes Chromosomes and Cancer. 2002 ; Vol. 35, No. 4. pp. 365-367.
@article{5acc8321f4cd4f659a6663238ecb0522,
title = "Identification of the breakpoints at 1p36.2 and 3p21.3 in an AML(M3) patient who had t(1;3)(p36.2;p21.3) at the third relapse",
abstract = "Recently, we reported that a recurrent translocation, t(1;3)(p36;p21) is closely associated with prior chemotherapy including alkylating agents, assessing eight patients with various hematologic malignancies (Genes, Chromosomes and Cancer 34:186- 192), 2002). Furthermore, we delineated the 1p36 breakpoint in two patients lying between RP11-BAC47P3 and RP5-PAC963K15 at 1p36.3 with a small deletion near the breakpoint. In one of them, we also found deletion at 3p21.3 with cosNRL9 probe, which is included in a 370-kb lung cancer homologous deletion region. However, due to scantiness of the patient materials at that time, we could not determine the precise breakpoint at 1p36 or 3p21 in any of the patients. In this report, we identified the 1p36 and 3p21 breakpoints of an AML (M3) patient who is included in the previous patient series. The patient showed t(1;3)(p36;p21) together with t(15;17) at the third relapse. With FISH using BAC/PAC probes, we determined the 1p36 breakpoint within RP11-295B1 at 1p36.2 and the 3p21 breakpoint between RP11-3B7 and RP11-901L6 at 3p21.3. There was no deletion around the two breakpoints in this patient. To the best of our knowledge, this is the first report that has identified the precise breakpoint of t(1;3)(p36;p21) transiocation. It is obvious that the 1p36.2 and 3p21.3 breakpoints of this patient are different from those of the previous patients, suggesting that the genes and the molecular event is different from those of the previous patients. The patients with t(1;3)(p36;p21) should be subclassified according to the precise breakpoints or the genes involved.",
author = "Tri, {Nguyen Khanh} and Xinh, {Phan Thi} and Hiromasa Nagao and Tohru Izumi and Keiya Ozawa and Atsushi Toyoda and Masahira Hattori and Yoshiyuki Sakaki and Katsushi Tokunaga and Yuko Sato",
year = "2002",
month = "12",
day = "1",
doi = "10.1002/gcc.10130",
language = "English",
volume = "35",
pages = "365--367",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Identification of the breakpoints at 1p36.2 and 3p21.3 in an AML(M3) patient who had t(1;3)(p36.2;p21.3) at the third relapse

AU - Tri, Nguyen Khanh

AU - Xinh, Phan Thi

AU - Nagao, Hiromasa

AU - Izumi, Tohru

AU - Ozawa, Keiya

AU - Toyoda, Atsushi

AU - Hattori, Masahira

AU - Sakaki, Yoshiyuki

AU - Tokunaga, Katsushi

AU - Sato, Yuko

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Recently, we reported that a recurrent translocation, t(1;3)(p36;p21) is closely associated with prior chemotherapy including alkylating agents, assessing eight patients with various hematologic malignancies (Genes, Chromosomes and Cancer 34:186- 192), 2002). Furthermore, we delineated the 1p36 breakpoint in two patients lying between RP11-BAC47P3 and RP5-PAC963K15 at 1p36.3 with a small deletion near the breakpoint. In one of them, we also found deletion at 3p21.3 with cosNRL9 probe, which is included in a 370-kb lung cancer homologous deletion region. However, due to scantiness of the patient materials at that time, we could not determine the precise breakpoint at 1p36 or 3p21 in any of the patients. In this report, we identified the 1p36 and 3p21 breakpoints of an AML (M3) patient who is included in the previous patient series. The patient showed t(1;3)(p36;p21) together with t(15;17) at the third relapse. With FISH using BAC/PAC probes, we determined the 1p36 breakpoint within RP11-295B1 at 1p36.2 and the 3p21 breakpoint between RP11-3B7 and RP11-901L6 at 3p21.3. There was no deletion around the two breakpoints in this patient. To the best of our knowledge, this is the first report that has identified the precise breakpoint of t(1;3)(p36;p21) transiocation. It is obvious that the 1p36.2 and 3p21.3 breakpoints of this patient are different from those of the previous patients, suggesting that the genes and the molecular event is different from those of the previous patients. The patients with t(1;3)(p36;p21) should be subclassified according to the precise breakpoints or the genes involved.

AB - Recently, we reported that a recurrent translocation, t(1;3)(p36;p21) is closely associated with prior chemotherapy including alkylating agents, assessing eight patients with various hematologic malignancies (Genes, Chromosomes and Cancer 34:186- 192), 2002). Furthermore, we delineated the 1p36 breakpoint in two patients lying between RP11-BAC47P3 and RP5-PAC963K15 at 1p36.3 with a small deletion near the breakpoint. In one of them, we also found deletion at 3p21.3 with cosNRL9 probe, which is included in a 370-kb lung cancer homologous deletion region. However, due to scantiness of the patient materials at that time, we could not determine the precise breakpoint at 1p36 or 3p21 in any of the patients. In this report, we identified the 1p36 and 3p21 breakpoints of an AML (M3) patient who is included in the previous patient series. The patient showed t(1;3)(p36;p21) together with t(15;17) at the third relapse. With FISH using BAC/PAC probes, we determined the 1p36 breakpoint within RP11-295B1 at 1p36.2 and the 3p21 breakpoint between RP11-3B7 and RP11-901L6 at 3p21.3. There was no deletion around the two breakpoints in this patient. To the best of our knowledge, this is the first report that has identified the precise breakpoint of t(1;3)(p36;p21) transiocation. It is obvious that the 1p36.2 and 3p21.3 breakpoints of this patient are different from those of the previous patients, suggesting that the genes and the molecular event is different from those of the previous patients. The patients with t(1;3)(p36;p21) should be subclassified according to the precise breakpoints or the genes involved.

UR - http://www.scopus.com/inward/record.url?scp=18644372249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18644372249&partnerID=8YFLogxK

U2 - 10.1002/gcc.10130

DO - 10.1002/gcc.10130

M3 - Article

VL - 35

SP - 365

EP - 367

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 4

ER -